Bottom line
What is NEMRX's expense ratio?
NEMRX's expense ratio is 1.6%, or about $160 a year on every $10,000 invested. That is more expensive than 87% of emerging markets funds we track (median 1.02%). Its expense ratio includes a 0.5% 12b-1 marketing fee.
Updated Feb 10, 2026
NEMRX fee table
| Net expense ratio | 1.6% |
|---|---|
| Gross expense ratio | 1.95% |
| Management fee | 1.01% |
| 12b-1 (distribution) fee | 0.5% |
| Other expenses | 0.44% |
| Fee waiver / reimbursement | -0.35% |
Source: Fund prospectus fee table, filed Feb 10, 2026
What NEMRX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| NEMRX | $163 | $505 | $949 | $2,185 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.6% expense ratio costs roughly $84,100 in lost growth, versus about $56,400 for the median emerging markets fund (1.02%).